










































Astrocyte-specific expression of hamster prion protein (PrP)
renders PrP knockout mice susceptible to hamster scrapie
Citation for published version:
Raeber, AJ, Race, RE, Brandner, S, Priola, SA, Sailer, A, Bessen, RA, Mucke, L, Manson, J, Aguzzi, A,
Oldstone, MBA, Weissmann, C & Chesebro, B 1997, 'Astrocyte-specific expression of hamster prion protein
(PrP) renders PrP knockout mice susceptible to hamster scrapie' EMBO Journal, vol. 16, no. 20, pp. 6057-
65.
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




© 1997 Oxford University Press
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
The EMBO Journal Vol.16 No.20 pp.6057–6065, 1997
Astrocyte-specific expression of hamster prion
protein (PrP) renders PrP knockout mice susceptible
to hamster scrapie
Alex J.Raeber, Richard E.Race1,
Sebastian Brandner2, Suzette A.Priola1,
Andreas Sailer3, Richard A.Bessen1,
Lennart Mucke4,5, Jean Manson6,
Adriano Aguzzi2, Michael B.A.Oldstone4,
Charles Weissmann7 and Bruce Chesebro1
Institut fu¨r Molekularbiologie, Abteilung I, University of Zu¨rich,
Ho¨nggerberg, 8093 Zu¨rich, 1Laboratory of Persistent Viral Diseases,
Rocky Mountain Laboratories, National Institute of Allergy and
Infectious Diseases, Hamilton, MT 59840, USA, 2Institut fu¨r
Neuropathologie, University Hospital Zu¨rich, 8091 Zu¨rich,
Switzerland, 4Division of Virology, Department of
Neuropharmacology, Scripps Research Institute, 10666 North Torrey
Pines Road, La Jolla, CA 92037, USA and 6Institute for Animal
Health, AFRC, Edinburgh, UK
3Present address: Molecular Neurobiology Laboratory, Salk Institute,
10010 North Torrey Pines Road, La Jolla, CA 92037, USA
5Present address: Gladstone Molecular Neurobiology Program,
PO Box 419100, San Francisco, CA 94141, USA
7Corresponding author
A.J.Raeber and R.E.Race contributed equally to this work
C.Weissmann and B.Chesebro share senior authorship
Transmissible spongiform encephalopathies are
characterized by spongiosis, astrocytosis and accumu-
lation of PrPSc, an isoform of the normal host protein
PrPC. The exact cell types responsible for agent propa-
gation and pathogenesis are still uncertain. To deter-
mine the possible role of astrocytes, we generated mice
devoid of murine PrP but expressing hamster PrP
transgenes driven by the astrocyte-specific GFAP pro-
moter. After inoculation with hamster scrapie, these
mice accumulated infectivity and PrPSc to high levels,
developed severe disease after 227 6 5 days and died
7 6 4 days later. Therefore, astrocytes could play an
important role in scrapie pathogenesis, possibly by an
indirect toxic effect on neurons. Interestingly, mice
expressing the same transgenes but also endogenous
murine PrP genes propagated infectivity without
developing disease.
Keywords: astrocytes/hamster scrapie prions/PrP/
transgenic mice
Introduction
Transmissible spongiform encephalopathies (TSEs) are
degenerative disorders of the central nervous system
(CNS) which occur naturally in man and in a variety of
other animals. They include scrapie of sheep and goats,
bovine spongiform encephalopathy (BSE) in cattle and
several human diseases such as Creutzfeldt–Jakob disease
(CJD), Kuru, Gerstmann–Stra¨ussler–Scheinker syndrome
(GSS) and fatal familial insomnia (FFI) (Pocchiari, 1994;
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Prusiner, 1996; Caughey and Chesebro, 1997). Since its
first recognition in 1986, BSE has acquired epidemic
proportions in the UK (Wilesmith, 1992), and the recent
appearance of a new variant of CJD (vCJD) has raised
concern that BSE might be communicable to humans
(Will et al., 1996). One of the hallmarks of TSE is the
accumulation in the brain of a protease-resistant protein,
PrPSc or PrP-res, which is derived by a poorly understood
post-translational event from a normal host-encoded pro-
tease-sensitive isoform, designated PrPC or PrP-sen
(Chesebro et al., 1985; Oesch et al., 1985; Basler et al.,
1986). PrPC is attached by a glycolipid anchor to the cell
surface (Stahl et al., 1987) and is expressed by many
cell types, including neurons (Kretzschmar et al., 1986),
astrocytes (Moser et al., 1995; van Keulen et al., 1995),
lymphocytes (Cashman et al., 1990), follicular dendritic
cells (McBride et al., 1992) and tumor cell lines of various
lineages (Caughey et al., 1988). Brain-derived preparations
highly enriched for scrapie infectivity contain PrPSc as a
major protein component (Bolton et al., 1982), but no
scrapie-specific nucleic acid has been detected (Kellings
et al., 1993). Prusiner suggested that the etiologic agent
of TSE might be PrPSc itself (Prusiner, 1982) and that
agent propagation might occur by a mechanism of PrPSc
induced conformational transition of PrPC into new PrPSc
molecules (Prusiner, 1989, 1991, 1993; Caughey et al.,
1991; Pan et al., 1993).
Mice devoid of functional PrP genes are resistant to
scrapie and unable to propagate the agent (Bu¨eler et al.,
1993; Sailer et al., 1994). Efficient cross-species transmis-
sion of TSE is dependent on expression of PrP from the
same species as the source of the challenge TSE agent
(Scott et al., 1989; Prusiner et al., 1990). Introduction of
hamster PrP (HaPrP) transgenes into PrP null mice restores
susceptibility to hamster scrapie but not to mouse scrapie,
and vice versa (Bu¨eler et al., 1993; Fischer et al., 1996).
The cell types involved in agent propagation have not
been completely identified. Some data indicate that in the
spleen (where in most models of scrapie, accumulation of
scrapie agent is first detected), the follicular dendritic cells
constitute the pathogenetic compartment (Kitamoto et al.,
1991; McBride et al., 1992). It is generally assumed that
agent propagation and pathology in the brain is neuron-
dependent, and it was recently shown that transgenic mice
expressing a hamster PrP minigene under the control of
the neuron-specific enolase (NSE) promoter are highly
susceptible to the hamster scrapie agent (Race et al., 1995).
In these mice, HaPrP expression was found exclusively in
neurons and not in glial cells or cells within the spleen or
lymph nodes. Thus, neuron-specific PrP expression is
sufficient to sustain scrapie infection, and PrP expression
in non-neuronal cells, in particular astrocytes and cells of
the lymphoreticular system, is not required, at least in the
case of intracerebral inoculation.
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The possibility that astrocytes might also contribute to
the natural disease process is suggested by the findings
that astrocytes express PrP (Moser et al., 1995), and that
in at least one model they are also the earliest site of
PrPSc accumulation in the brain (Diedrich et al., 1991).
Here we show that PrP knockout mice transgenic for an
HaPrP gene under control of the glial fibrillary acidic
protein (GFAP) gene promoter express PrP predominantly
if not exclusively in astrocytes, and are susceptible to
intracerebral inoculation with hamster scrapie agent. These
mice accumulate protease-resistant HaPrP and high titers
of hamster scrapie agent in their brains, and show patho-
logical changes similar to those of non-transgenic wild-
type mice inoculated with mouse scrapie. Interestingly,
mice expressing the same transgenes as well as endogenous
murine PrP genes propagated infectivity without develop-
ing disease.
Results
Generation and characterization of GFAP-HaPrP
transgenic mice
To investigate whether astrocyte-restricted expression of
HaPrP suffices to render mice susceptible to hamster
scrapie agent, transgenic mice were generated in which a
1 kb cDNA encompassing the entire HaPrP open reading
frame was expressed under control of the glial fibrillary
acidic protein (GFAP) promoter (Johnson et al., 1995)
(Figure 1A). Transgene-positive founder mice were bred
to C57Bl/10 mice and positive F1 progeny were identified.
Among five independent founder lines, Tg3 mice showed
the highest level of PrP expression in the brain (Figure
1B). These mice expressed HaPrP mRNA in the brain
(Figure 1C). Western analysis revealed HaPrP protein in
the brain but not in spleen, heart, lung, thymus, muscle,
liver or kidney (Figure 1D). Tg3 mice were crossed with
PrP null (Prnp0/0) mice (Bu¨eler et al., 1992) to yield Tg3/
Prnp0/1 offspring which were intercrossed to produce Tg3/
Prnp0/0 mice. In initial experiments, the HaPrP mRNA
expression level in the brains of these mice was below
detectability by in situ hybridization. Therefore, we
examined the cell specificity of HaPrP expression after
cryolesion-mediated upregulation of GFAP-directed trans-
gene expression (Johnson et al., 1995). Brain sections
from Tg3/Prnp0/0 mice sacrificed 48 h after cryolesioning
were subjected to in situ hybridization for HaPrP followed
by immunohistochemistry for GFAP. As shown in Figure
2G, cells in the vicinity of the lesion that contained PrP
mRNA also expressed GFAP. In GFAP-positive cells of
the hippocampus (Figure 2D), PrP mRNA was expressed
to a lesser extent, perhaps because of its distance from
the lesioned site or because GFAP protein is more stable
than PrP mRNA. For comparison, Figure 2 shows that in
the hippocampal formation and also in the cerebral cortex
of Prnp1/1 mice, neurons were strongly positive for PrP
mRNA, while no PrP transcripts were detected in brains
of non-transgenic Prnp0/0 mice (compare panels F and I
with E and H). These findings indicated that in the
brain, the GFAP-HaPrP transgene was expressed only in
astrocytes. Experiments were then initiated to study the
susceptibility of these mice to hamster scrapie agent.
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Susceptibility of GFAP-HaPrP transgenic mice to
hamster scrapie
When Tg3 mice and non-transgenic littermates were
inoculated with hamster scrapie agent (strain 263K),
neither group developed disease by as late as 750 days after
inoculation, whereas all hamsters which were similarly
inoculated died of scrapie by 77 6 3 days (Figure 3). In
contrast, when Tg3/Prnp0/0 mice were challenged with
hamster scrapie, the mice developed severe scrapie symp-
toms consisting of ataxia, paralysis, kyphosis, foot clasp
reflex, mincing gait and disorientation around 227 6 5
days, and died at 233 6 3 days post-inoculation. Interest-
ingly, disease in these mice presented with a short clinical
disease period of only 7 6 4 days, as compared with
13 6 11 days for wild-type (CD-1) mice inoculated with
RML mouse scrapie (Bu¨eler et al., 1994), suggesting
unusual kinetics of the onset and development of patho-
genic processes. In a second experiment, the Tg3 trans-
genes were introduced into PrP knockout mice on a
different genetic background (129/Ola) (Manson et al.,
1994a), to yield RML-Tg3/Prnp–/– mice. After inoculation
with hamster scrapie agent (strain 263K), 9 out of 12
mice developed disease and died as in the previous
experiment, one animal developed disease 462 days after
inoculation and two mice which did not show clinical
symptoms were sacrificed 564 days after inoculation and
found to have high levels of PrPSc in their brains. Thus,
in almost all cases, expression of HaPrP in astrocytes was
sufficient to confer susceptibility to clinical disease in
Prnp0/0 mice, but not in Prnp1/1 mice. These results
demonstrated the profound influence of endogenous
murine PrPC on the susceptibility of HaPrP-transgenic
mice to hamster scrapie agent; similar interference of
endogenous murine PrP with pathogenicity of TSE agents
from other species has been described previously (Scott
et al., 1989; Race et al., 1995; Telling et al., 1996).
Protease-resistant HaPrP in transgenic GFAP-HaPrP
mice
One of the hallmarks of TSE diseases is the accumulation
in the brain of a protease-resistant isoform of PrP termed
PrPSc. We assessed the formation of PrPSc in scrapie-
infected transgenic mice by Western immunoblot analysis
of brain extracts using the HaPrP-specific monoclonal
antibody 3F4 (Kascsak et al., 1987). Although the level
of hamster PrPC in uninfected Tg3/Prnp0/0 mice was only
about 5% of the level detected in normal hamster brain
(Figure 4A, lanes 1 and 5), terminally ill scrapie-inoculated
Tg3/Prnp0/0 mice showed similar high levels of protease-
resistant PrP to clinically ill hamsters (Figure 4B). The
inordinately increased level of total HaPrP in scrapie-
infected as compared with uninfected Tg3/Prnp0/0 mice
(Figure 4A, compare lanes 1 and 3) could be due to
increased expression of HaPrP as a consequence of astro-
gliosis, in addition to the accumulation of HaPrPSc.
Northern blot analysis of poly(A)1 RNA showed a 2-fold
increase in HaPrP transcript level in the brains of Tg3/
Prnp0/0 mice in response to scrapie infection, in contrast
to the levels in wild-type mice which were not altered by
scrapie infection (Figure 4C, compare lanes 5 and 6 with
7 and 8).
Surprisingly, asymptomatic Tg3/Prnp1/1 mice sacrificed
at 300, 630 or 750 days post-inoculation also had detectable
PrP expression in astrocytes
Fig. 1. Structure of the GFAP-HaPrP transgene and characterization of the transgenic mice. (A) Partial structure of the GFAP-HaPrP transgene and
predicted mRNA. A 1.2 kb fragment of hamster PrP (HaPrP) cDNA (Robakis et al., 1986) containing the open reading frame, some untranslated PrP
sequences and Bluescript polylinker sequences was used to replace the lacZ gene between the NotI sites in clone C-445 (Johnson et al., 1995). This
construct contained ~2 kb of GFAP 59 flanking sequences, 89 residues of GFAP exon1, 0.2 kb of SV40 DNA with splice sites, the 1.2 kb HaPrP
insert, 0.2 kb of SV40 DNA with a poly(A) signal sequence, followed by the remainder of the GFAP gene. This construct was expected to produce a
messenger RNA of 1.8 kb, as shown. (B) Analysis of HaPrPC in brain by immunoblotting. Brain homogenates were prepared from uninfected
hamsters and F1 crosses of GFAP-HaPrP transgenic founder mice with C57BL/10 mice and were analyzed by immunoblotting with HaPrP-specific
monoclonal antibody 3F4. (C) Analysis of PrP mRNA in brain. mRNA from normal and Tg3 mouse brain was analyzed by Northern blotting as
described in Materials and methods. A 2.3 kb mRNA representing the normal mouse PrP transcript was seen in both samples, and a 1.8 kb mRNA
corresponding to the predicted transcript from the GFAP-HaPrP transgene was detected in Tg3 mice. (D) Immunoblot analysis of HaPrPC in various
tissues of hamster and Tg3 transgenic mice using monoclonal antibody 3F4. Each lane contained protein derived from 5 mg of tissue.
PrPSc, but quantitation by serial dilution showed that its
level was at least 100-fold lower than that observed in
terminally ill hamsters or Tg3/Prnp0/0 mice (Figure 4B).
A correlation between PrPSc level and clinical disease is,
however, not a general finding (Bu¨eler et al., 1994;
Collinge et al., 1995; Telling et al., 1996).
Propagation of hamster scrapie agent in
transgenic GFAP-HaPrP mice
To determine whether hamster scrapie agent was propa-
gated in the brains of asymptomatic Tg3/Prnp1/1 mice
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or non-transgenic littermates, brain homogenates from
animals sacrificed at various times after inoculation were
injected intracerebrally into hamsters. Recipients of brain
homogenate from Tg3/Prnp1/1 mice died after 90–95
days, which corresponds to a titer of ~23107–23108 LD50
units/g of brain tissue, whereas samples from clinically
ill Tg3/Prnp0/0 mice had 23109–231010 LD50 units/g
(Table I). In contrast, non-transgenic control mice had
much less hamster scrapie infectivity, corresponding to a
level of 20–2000 LD50 units/g. Thus, the presence of
normal mouse PrP reduced formation of HaPrPSc and
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Fig. 2. Brain sections doubly labeled for PrP mRNA and GFAP. Double labeling of Prnp mRNA (black) and GFAP (red) on sections of cryolesioned
brain of Tg3/Prnp0/0 mice (left column), Prnp0/0 mice (middle column) and wild-type mice (right column) 48 h after cryolesioning (Phillips et al.,
1995) of the right frontoparietal cortex (duration 60 s). At low power magnification (A, B and C), the necrotic zone and the penumbra of the
cryolesion appear demarcated by reactive astrocytes. Labeled rectangles indicate the detailed view of the respective area, hippocampus or penumbra
zone of the cortex. In Tg3/Prnp0/0 mice, coexpression of HaPrP mRNA (black) and GFAP (red) is visible after strong activation of the GFAP
promoter in the penumbra zone of the cryolesion (G), while HaPrP mRNA is barely detectable in resting astrocytes (D). Prnp0/0 mice show activated
astrocytes around cryolesioned areas (H) and resting astrocytes in the hippocampus (E), but no PrP mRNA. Wild-type mice show PrP mRNA in
hippocampal (F) and cortical neurons (I) but not in activated (I) or resting (F) astrocytes.
Fig. 3. Kinetics of death due to scrapie of animals inoculated intracerebrally with hamster scrapie agent. (d) Hamsters (N 5 13) inoculated with
strain 263K. (s) RML-Tg3/Prnp–/– mice (N 5 12) inoculated with strain 263K. One mouse developed scrapie-like disease 462 days post-inoculation
(arrow) and was sacrificed 564 days after inoculation. No PrPSc was detected in the brain of this mouse. Two mice were sacrificed 564 days after
inoculation (arrowhead). Both of these mice had PrPSc levels in their brains similar to a scrapie sick hamster. One of these mice was listless and
ataxic; this same mouse had collapsed cerebral hemispheres at necropsy. The other mouse was listless but did not show any other clinical symptoms.
(j) Zu¨rich-Tg3/Prnp0/0 mice (N 5 8) inoculated with strain Sc237. (m) Non-transgenic mice C57BL/10 (N 5 10) inoculated with 263K showed no
clinical disease during the period of observation (750 days). ‘Death times’ represent interval to a moribund condition or in a few cases, to actual
death.
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PrP expression in astrocytes
Fig. 4. Detection of HaPrPSc and PrP mRNA in organ homogenates.
(A) Western analysis of proteinase K-digested samples (even-
numbered lanes) and untreated samples (odd-numbered lanes). Lanes
1–4, Tg3/Prnp0/0 mouse uninoculated (lanes 1 and 2) or inoculated
with Sc237 hamster scrapie agent and terminally scrapie sick (lanes 3
and 4). Lanes 5–8, hamster uninoculated (lanes 5 and 6) or inoculated
and terminally scrapie sick (lanes 7 and 8). Lane 9, Prnp0/0 mouse, not
inoculated. Molecular weight markers are depicted on the left with
molecular masses expressed in kDa. (B) Western analysis of serial
5-fold dilutions of proteinase K-treated brain extracts from hamsters
[75 days post-inoculation (d)], Tg3 (Prnp1/1) mice (630 d and 750 d),
and from Tg3/Prnp0/0 (231 d). Molecular weight markers are indicated
on the left with molecular masses expressed in KDa. (C) Northern
analysis of poly(A)1 RNA (equivalent of 50 µg of total RNA per
lane) in spleens (lanes 1–4) and brains (lanes 5–9) of wild-type mice
uninoculated (lanes 1 and 5) or inoculated with RML mouse scrapie
agent and terminally scrapie sick (lanes 2 and 6) and Tg3/Prnp0/0 mice
uninoculated (lanes 3 and 7) or inoculated with Sc237 hamster scrapie
agent and terminally sick (lanes 4 and 8). Lane 9, brain of Prnp0/0, not
inoculated. After autoradiography the filter was stripped and
successively hybridized with a GFAP and a GAPDH probe.
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hamster scrapie infectivity and prevented clinical disease
in Tg3/Prnp1/1 mice.
Low levels of hamster scrapie infectivity were detected
in the spleen of a Tg3/Prnp0/0 mouse sacrificed 233 days
after intracerebral (i.c.) inoculation. This could either be
due to transport of residual inoculum or of scrapie agent
formed in the CNS to the lymphoreticular system, or
represent propagation of infectivity in the spleen. The
latter interpretation, if correct, could be explained by the
presence of low levels of HaPrP mRNA in the spleens of
both uninfected and scrapie-infected Tg3/Prnp0/0 mice.
The GFAP promoter is therefore active in spleen tissue,
as shown by the presence of low levels of GFAP mRNA
in wild-type spleen (Figure 4C, lanes 1 and 2) and in Tg3/
Prnp0/0 spleen (lanes 3 and 4, visible on the original film
but not in the photograph).
Neuropathology in scrapie-inoculated mice
In the brains of clinically ill Tg3/Prnp0/0 mice inoculated
with hamster agent, spongiform changes and pronounced
astrogliosis were found predominantly in the neocortex
and hippocampus, with no significant difference between
Tg3/Prnp0/0 transgenic mice inoculated with hamster
scrapie and normal mice inoculated with mouse scrapie
(Figure 5). Therefore, typical scrapie neuropathology could
be observed when PrP was expressed in astrocytes and
not in neurons.
Discussion
Spongiosis, astrocytosis and accumulation of PrPSc are
the most prominent neuropathological features associated
with TSEs; neuronal loss is not consistently found in mouse
scrapie (Scott and Fraser, 1984; S.Brandner, unpublished
observations). While neurons are clearly affected in the
disease process, it is still unclear whether other brain cells
also play a role. Recently it was demonstrated that neuron-
specific expression of HaPrP driven by the NSE promoter
in transgenic mice is sufficient to mediate susceptibility
to hamster scrapie (Race et al., 1995). However, astrocytes
may also participate in scrapie pathogenesis because these
cells show marked morphological abnormalities early in
the disease process (Pattison, 1965; Eklund et al., 1967),
and may in some cases be the earliest site of accumulation
of PrPSc in the brain (Diedrich et al., 1991).
In the present paper we report on transgenic mice
expressing HaPrP under control of the GFAP promoter.
The GFAP expression vector used for generating GFAP-
HaPrP transgenic mice was shown previously to confer
astrocyte-specific expression upon a lacZ reporter trans-
gene (Mucke et al., 1991). In these experiments, lacZ
expression was restricted to astrocytes in the CNS and
lens epithelium, and was not observed in neurons or in
other tissues including spleen, lymph node and sciatic
nerve. In the GFAP-HaPrP mice described in the present
report, HaPrP protein was found only in the brain and
was below detection levels in other tissues. Although the
constitutive level of HaPrP in the brains of transgenic
mice was only ~5% of that observed in normal hamster
brain, the GFAP-HaPrP transgene was up-regulated after
cryolesioning and after infection with hamster scrapie.
Within the limits of detection in vivo, HaPrP mRNA co-
localized exclusively with GFAP-positive cells in brain
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Table I. Bioassay of hamster scrapie infectivity from mouse brains
Donor genotypea Organ Days p.i. Log10 dilutionb Days to deathc LD50/g
Prnp1/1 (non-tg) brain 300 –2 178 6 14 (3) 2.101
Prnp1/1 (non-tg) brain 630 –2 123 6 23 (15) 2.103
Tg3/Prnp1/1 brain 300 –2 95 6 3 (10) 2.107
Tg3/Prnp1/1 brain 630 –2 90 6 2 (12) 2.108
Tg3/Prnp0/0 brain 231 –3 83 6 4 (5) 2.1010
Tg3/Prnp0/0 brain 233 –3 90 6 4 (6) 2.109
Tg3/Prnp0/0 brain 235 –3 91 6 5 (6) 2.109
Tg3/Prnp0/0 spleen 233 –2 212 6 16 (3) 1–10
Hamster brain 75 –3 83 6 2 (6) 2.1010
a Donor animals were inoculated i.c. with hamster scrapie agent as described in Materials and methods.
b10% (w/v) suspensions of tissue in either 0.32 M sucrose or 10 mM Tris–HCl, 5 mM MgCl2 (5 10–1 dilution) were made, and the dilutions
indicated in the table were inoculated i.c. into hamsters.
c Mean days to death 6 standard deviation (number of hamsters inoculated). All inoculated hamsters died of scrapie.
Fig. 5. Neuropathology in terminally ill scrapie-infected mice. Hematoxylin and eosin staining (A–C) and GFAP immunohistochemistry (D–F) of the
hippocampus of a Sc237 hamster scrapie-inoculated Tg3/Prnp0/0 mouse (238 days post-inoculation) (A and D), wild-type mouse inoculated with
RML mouse scrapie (166 days post inoculation) (B and E) and RML-inoculated Prnp0/0 mouse (365 days post inoculation) (C and F). Prominent
spongiosis and gliosis were found in the brains of scrapie-infected transgenic and wild-type mice. Histopathological analyses were performed when
mice showed clinical symptoms of scrapie. No notable differences in the pathological changes between transgenic and wild-type mice were
observed.
sections of Tg3/Prnp0/0 mice, as expected from the astro-
cyte specificity of the GFAP promoter (Johnson et al.,
1995). There was no evidence for HaPrP expression in
neurons, and if any occurred, it would be at very low
levels and unlikely to contribute to pathogenesis. No
HaPrP protein was seen in spleen by immunoblotting,
although HaPrP mRNA was detected at low levels.
Inoculation of Tg3/Prnp0/0 mice with hamster scrapie
agent resulted in neurological disease after a relatively
long incubation time of 227 days. This was not unexpected
in view of the dependence of incubation time on PrPC
expression levels (Prusiner et al., 1990; Bu¨eler et al.,
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1994; Manson et al., 1994b; Fischer et al., 1996). More
surprising was the rapid progression of the clinical phase
leading to death of all animals within about a week. This
might be explained by the inducible nature of the GFAP-
HaPrP transgene leading to increased levels of HaPrPC
after astrocyte activation, thereby providing more substrate
for the conversion of HaPrPC into HaPrPSc.
In the present experiments, expression of mouse PrP
in GFAP-HaPrP transgenic mice completely prevented
clinical disease, and diminished HaPrPSc formation and
propagation of hamster scrapie agent. Similar competitive
or inhibitory effects between coexpressed PrP molecules
PrP expression in astrocytes
of different species have been noted previously both in
transgenic mice (Scott et al., 1989, 1992; Telling et al.,
1996) and in mouse neuroblastoma cell cultures (Scott
et al., 1992; Priola et al., 1994; Priola and Chesebro,
1995; Race et al., 1995) These results indicate, once more
(Bu¨eler et al., 1994; Manson et al., 1994b), that agent
propagation to high levels is not necessarily sufficient to
cause pathology or clinical symptoms.
In the course of the disease in wild-type mice, PrPSc
has been found to accumulate in astrocytes prior to the
development of neuropathological changes (Diedrich et al.,
1991), suggesting that PrPSc released into the extracellular
compartment (Jeffrey et al., 1994) might contribute to
pathogenesis by inherent toxicity. However, as shown
recently (Brandner et al., 1996), PrPSc was unable to elicit
a neurotoxic effect when presented to PrP0/0 neural tissue;
neurotoxicity only resulted when cells were PrP1/1 and
thus able to produce PrPSc endogenously. Tg3/Prnp0/0 mice
express HaPrPC in astrocytes but not in neurons, and
therefore in these animals only astrocytes should be
susceptible to direct pathological effects mediated by
PrPSc. However, because astrocytes are involved in main-
taining the normal status of neurons (Mucke and Eddleston,
1993), astrocyte dysfunction might result in neuronal
abnormalities. Interestingly, onset and development of
neuropathological changes in scrapie correlate with
increased expression of a variety of cytokines (Campbell
et al., 1994; Williams et al., 1994). Such cytokines might
be produced by astrocytes or other glial cells, and might
play a key role in the pathological events of scrapie via
indirect effects leading to neuronal dysfunction, analogous
to that which has been seen following infection of glial
cells by murine retroviruses which cause a spongiform
pathology quite like scrapie (Lynch et al., 1991).
Our findings that astrocytosis and spongiosis in the
terminal phase of scrapie are quite similar in wild-type
mice and in mice expressing PrP in either neurons or
astrocytes only, suggest that a common final pathway,
perhaps cytokine overproduction, contributes to the neuro-
pathological picture in all these cases.
Materials and methods
Generation of transgenic mice
A 1 kb fragment of hamster PrP cDNA containing the open reading
frame was cloned into pBluescript-KS1 to generate plasmid p2–17, as
described previously (Race et al., 1995). A NotI linker was added at the
KpnI site in the polylinker and a 1.2 kb fragment was excised with NotI
and inserted in place of the lacZ gene in clone C-445 containing a
modified GFAP gene (Johnson et al., 1995). Digestion of this plasmid
with SfiI to remove the vector sequences yielded the DNA fragment
used to generate GFAP-HaPrP transgenic mice. Microinjection into
pronuclei of fertilized oocytes was according to standard procedures.
Transgene-positive founders were identified by semiquantitative dot blot
hybridization and further characterized by Southern analysis of tail DNA,
using an HaPrP DNA probe. Five lines (Tg3 to Tg7) had about two to
four transgene copies. Tg3 mice were crossed with Prnp0/0 mice (Bu¨eler
et al., 1992) in Zu¨rich and with Prnp–/– mice (Manson et al., 1994a) at
RML; F3 PrP knockout progeny carrying the hamster PrP transgenes
were identified by hamster-specific PCR on tail DNA. In Zu¨rich, two
separate PCRs were performed; the mouse Prnp0 and Prnp1 alleles were
detected by the three primers RK1, RK2 and RK3 (Prusiner et al., 1993),
and the hamster PrP transgene was amplified using the two primers
GFAP1 (59)AACCGTTACCCACCTCAGGGT and GFAP2 (59)CTCCT-
TCTGATACTGGGTGGT to yield a 521 bp product. The reactions were
performed in 25 µl containing 10 mM Tris–HCl (pH 9.0), 50 mM KCl,
0.1% Triton X-100, 1.5 mM MgCl2, 0.2 mM dNTP, 50 µM of each
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primer and 0.1 units SuperTaq DNA polymerase. Amplification was
carried out by cycling 35 times for 1 min at 94°C, 1 min at 60°C and
for 45 s at 72°C. At RML, three reactions were used. One of the reactions
identified mice positive for HaPrP. The oligonucleotide sequences and
reaction conditions have been described (Race et al., 1995). A second
set of oligonucleotide primers specific for a portion of the neomycin
resistance gene was used to identify mice containing the disrupted non-
functional mouse (Mo) PrP gene (39-CTTGGACGCACGTTAGGTAG-
59) and (59-TTGAGCCTGGCGAACAGTTC-39). The third set of
primers, specific for MoPrP, distinguished mice heterozygous for the
disrupted MoPrP from those homozygous for the disrupted MoPrP gene
(59AACCGTTACCCACCTCAGGGT-39) and (39-ACACTTCTACTAC-
CTCGCG-59). The same conditions were used for all three PCRs.
Sources of infectious scrapie agent
RML (Chandler, 1961) is a mouse-adapted scrapie isolate which was
passaged in Swiss CD-1 mice obtained from Charles River Laboratories.
The Syrian hamster-adapted isolate of scrapie strain 263K (Kimberlin
and Walker, 1978) was passaged repeatedly in Golden Syrian hamsters.
The Sc237 isolate (Scott et al., 1989) was provided by S.B.Prusiner.
Scrapie infection and diagnosis
Hamsters and mice were inoculated i.c. with 50 and 30 µl, respectively,
of a 1% brain suspension of scrapie-infected hamster brain. Brain
homogenates were made from several of the Tg3/Prnp0/0 and Tg3/Prnp1/1
mice at different times after inoculation. To titrate the levels of infectivity,
50 µl of various dilutions of these brain homogenates were inoculated
i.c. into weanling Syrian hamsters which were then inspected two or
three times per week for the appearance of scrapie symptoms.
Northern analysis
For the experiment in Figure 1C, brain poly(A)1 RNA was isolated
using a micro Fast-Track kit (Invitrogen) and was analyzed as previously
described (Race et al., 1995). For Figure 4C, total brain RNA was
prepared as described previously (Chomczynski and Sacchi, 1987), and
poly(A)1 RNA was isolated using oligo-(dT) latex beads (Qiagen)
according to the manufacturer’s instructions. Poly(A)1 RNA was de-
natured, electrophoresed through 2.2 M formaldehyde–1% agarose gels
and blotted onto Hybond-N1 (Amersham) membranes in 203 SSC.
Prehybridization and hybridization were performed with Quickhyb
(Stratagene) according to the manufacturer’s instructions. The membranes
were probed with the 256 bp KpnI–BstEII fragment of the hamster PrP
ORF which was 32P-labeled by the random primer method (Prime-It,
Stratagene). GFAP mRNA was detected with a mouse GFAP cDNA
probe (a kind gift from U.Pott, Brain Research Institute, University of
Zu¨rich). For glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA
as an internal standard, the 490 bp XhoII fragment from rat GAPDH
subcloned into pSP64 was used as a probe (Fort et al., 1985).
Western blot analysis
For Figure 1B and D and Figure 4B, proteins were analyzed by
immunoblot as previously described (Race et al., 1995). For Figure 4A,
10% brain homogenates were prepared in PBS containing 0.5% NP40
and 0.5% sodium deoxycholate by passing the brains through 18-gauge
and 22-gauge needles. The homogenate was centrifuged at 1500 g for
10 min, and the supernatant was adjusted to 8 mg/ml of total protein
using the BCA protein assay according to the manufacturer’s instruction
(Pierce). Where indicated, aliquots of the homogenate were digested
with 20 µg/ml proteinase K for 30 min at 37°C, and the reactions were
stopped by adding PMSF to 2 mM and boiling in SDS–PAGE loading
buffer without β-mercaptoethanol. The samples (80 µg of total protein)
were electrophoresed through 12% SDS–polyacrylamide gels. Proteins
were transferred to nitrocellulose membranes and probed with mono-
clonal antibody to hamster PrP [3F4, 1:10000 (Kascsak et al., 1987)],
developed using the enhanced chemiluminescence kit (Amersham) and
exposed to Kodak X-ray film.
In situ hybridization
In situ hybridization for PrP RNA was performed on selected brain
sections. The 290 bp (Asp718–BstEII) fragment of mouse PrP cDNA
was cloned into pBluescript KS and SK vector (Stratagene, La Jolla,
CA), respectively. Digoxygenin-labeled sense and antisense probes were
synthesized (Boehringer, Mannheim) from the Asp718-cleaved KS and
SK constructs, respectively, using T3 RNA polymerase. Sections were
deparaffinized and postfixed in 4% paraformaldehyde in PBS, mildly
digested with proteinase K (10 µg/ml for 5 min at 37°C) and permeabil-
ized for 10 min in 0.1 M HCl. After a second fixation step in 4%
A.J.Raeber et al.
paraformaldehyde for 10 min, acetylation was performed in triethanol-
amine 0.1 M, acetic anhydride 0.25% and prehybridization was carried
out in 53 SSC, 50% formamide, 53 Denhardt’s and 250 µg/ml yeast
tRNA for 3–5 h at room temperature. Hybridization was in the same
mixture containing the digoxygenin-labeled probe at 200–400 ng/ml for
12 h at 65°C. The sample was washed for 1 h at 65°C in 0.23 SSC,
labeled with anti-DIG Fab fragments (1:500) and developed with
5-bromo-4-chloro-3-indolyl phosphate and 4-nitroblue tetrazolium
chloride following the supplier’s protocol. For subsequent GFAP
immunolabeling, sections were heated to 80°C to inactivate alkaline
phosphatase and processed as described below. The sections were
mounted in glycerol–gelatin.
Immunohistochemistry
For paraffin histology, whole mouse brains were fixed for at least 24 h
in 4% paraformaldehyde in phosphate-buffered saline (PBS), immersed
for 1 h in 98% formic acid and postfixed for 72 h in 4% paraformaldehyde/
PBS. Coronal slices of ~2 mm thickness were dehydrated through graded
alcohols and embedded in paraffin. Sections of 4 µm nominal thickness
were mounted on TESPA (SIGMA Chemicals)-coated glass slides and
routinely stained with hematoxylin and eosin (H&E). Immunohisto-
chemistry for GFAP [polyclonal, 1:300 (Dako, Glostrup, DK)] was
performed on paraffin-embedded sections. Biotinylated secondary anti-
bodies (goat anti-rabbit; DAKO) were used at a dilution of 1:200.
Visualization was achieved using biotin/avidin-peroxidase (DAKO) and
diaminobenzidine as a chromogen following the protocols suggested by
the manufacturer. Alkaline phosphatase-labeled secondary antibodies
(rabbit anti-mouse, DAKO) were used at a 1:30 dilution and visualized
by the new fuchsin color reaction according to manufacturer’s protocol.
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